Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 20/01/20101 min de lecture
Prospective Grant of Exclusive License: Monoclonal Antibodies Against Smallpox/Orthopoxviruses
Traduction automatique locale · Langue originale de la source
Résumé
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a an exclusive license to practice the following invention as embodied in the following patent applications: E-145-2004/0,1,2,3,4, Purcell et al., "Monoclonal Antibodies Against Orthopoxviruses", United States Patent Application 12/142,594, filed June 19, 2008 to BioFactura, Inc., having a place of business in Rockville, Maryland. The patent rights in this invention have been assigned to the United States of America.
Langue originale de la source: Federal Register — Health and Human ServicesOuvrir le communiqué original →